Xinyi Yang1, Lay Poh Khoo2, Esther Wei Yin Chang2,3, Valerie Shiwen Yang2,3,4, Eileen Poon2,3,5, Nagavalli Somasundaram2,3,5, Mohamad Farid2,3,5, Tiffany Pooi Ling Tang2,3,5, Miriam Tao2,3,5, Soon Thye Lim6,7,8, Jason Yongsheng Chan9,10,11,12. 1. Yong Loo Lin School of Medicine, National University of Singapore, Singapore City, Singapore. 2. Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore City, 169610, Singapore. 3. SingHealth Duke-NUS Blood Cancer Centre, Singapore City, Singapore. 4. Institute of Molecular and Cell Biology, Singapore City, Singapore. 5. Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore City, Singapore. 6. Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore City, 169610, Singapore. lim.soon.thye@singhealth.com.sg. 7. SingHealth Duke-NUS Blood Cancer Centre, Singapore City, Singapore. lim.soon.thye@singhealth.com.sg. 8. Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore City, Singapore. lim.soon.thye@singhealth.com.sg. 9. Division of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore City, 169610, Singapore. Jason.chan.y.s@nccs.com.sg. 10. SingHealth Duke-NUS Blood Cancer Centre, Singapore City, Singapore. Jason.chan.y.s@nccs.com.sg. 11. Oncology Academic Clinical Program, Duke-NUS Medical School, Singapore City, Singapore. Jason.chan.y.s@nccs.com.sg. 12. Cancer Science Institute of Singapore, National University of Singapore, Singapore City, Singapore. Jason.chan.y.s@nccs.com.sg.
Abstract
BACKGROUND: Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerate these agents nor derive benefit. We investigated the impact of age on treatment patterns and clinical outcomes of MCL patients in an Asian population. METHODS: A retrospective study was conducted on patients (n = 66) diagnosed with MCL at the National Cancer Centre Singapore between 1998 and 2018. The median follow-up duration was 40 months. Survival analyses were performed using the Kaplan-Meier method and multivariate Cox proportional models. RESULTS: The median age of the cohort was 59 years (range, 26-84), with a male predominance (73%). The majority (86%) had advanced stage 3-4 disease at diagnosis. Compared with younger patients, older patients aged ≥60 years (n = 32; 48.5%) presented more frequently with B-symptoms (75% vs 38%, p = 0.0028), anaemia (75% vs 35%, p = 0.0013), and carried higher prognostic risk scores (sMIPI high risk 84% vs 56%, p = 0.016). Non-cytarabine-based induction chemotherapy was more commonly administered in older patients (76% vs 32%, p = 0.0012). The 5-year overall survival (OS) and progression-free survival (PFS) was 68 and 25% respectively. In a multivariable model, older age (HR 3.42, 95%CI 1.48-7.92, p = 0.004) and anemia (HR 2.56, 95%CI 1.10-5.96, p = 0.029) were independently associated with poorer OS while older age (HR 2.24, 95%CI 1.21-4.14, p = 0.010) and hypoalbuminemia (HR 2.20, 95%CI 1.17-4.13, p = 0.014) were independently associated with poorer PFS. In an exploratory analysis, maintenance rituximab following induction chemotherapy improved PFS in younger patients, with median PFS of 131 months and 45 months with or without maintenance therapy respectively (HR 0.39, 95%CI 0.16-0.93, p = 0.035). In contrast, no survival benefit was observed in older patients. CONCLUSIONS: We demonstrated in our analysis that older patients with MCL may harbor adverse clinical features and may not derive benefit from maintenance rituximab, highlighting the need for further research in this area of need.
BACKGROUND: Significant progress has been made in the treatment outcomes of mantle cell lymphoma (MCL) since the introduction of cytarabine and rituximab in modern regimens. However, older patients may not readily tolerate these agents nor derive benefit. We investigated the impact of age on treatment patterns and clinical outcomes of MCLpatients in an Asian population. METHODS: A retrospective study was conducted on patients (n = 66) diagnosed with MCL at the National Cancer Centre Singapore between 1998 and 2018. The median follow-up duration was 40 months. Survival analyses were performed using the Kaplan-Meier method and multivariate Cox proportional models. RESULTS: The median age of the cohort was 59 years (range, 26-84), with a male predominance (73%). The majority (86%) had advanced stage 3-4 disease at diagnosis. Compared with younger patients, older patients aged ≥60 years (n = 32; 48.5%) presented more frequently with B-symptoms (75% vs 38%, p = 0.0028), anaemia (75% vs 35%, p = 0.0013), and carried higher prognostic risk scores (sMIPI high risk 84% vs 56%, p = 0.016). Non-cytarabine-based induction chemotherapy was more commonly administered in older patients (76% vs 32%, p = 0.0012). The 5-year overall survival (OS) and progression-free survival (PFS) was 68 and 25% respectively. In a multivariable model, older age (HR 3.42, 95%CI 1.48-7.92, p = 0.004) and anemia (HR 2.56, 95%CI 1.10-5.96, p = 0.029) were independently associated with poorer OS while older age (HR 2.24, 95%CI 1.21-4.14, p = 0.010) and hypoalbuminemia (HR 2.20, 95%CI 1.17-4.13, p = 0.014) were independently associated with poorer PFS. In an exploratory analysis, maintenance rituximab following induction chemotherapy improved PFS in younger patients, with median PFS of 131 months and 45 months with or without maintenance therapy respectively (HR 0.39, 95%CI 0.16-0.93, p = 0.035). In contrast, no survival benefit was observed in older patients. CONCLUSIONS: We demonstrated in our analysis that older patients with MCL may harbor adverse clinical features and may not derive benefit from maintenance rituximab, highlighting the need for further research in this area of need.
Authors: Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger Journal: Lancet Date: 2013-02-20 Impact factor: 79.321
Authors: Jorge E Romaguera; Luis Fayad; Maria A Rodriguez; Kristine R Broglio; Frederick B Hagemeister; Barbara Pro; Peter McLaughlin; Anas Younes; Felipe Samaniego; Andre Goy; Andreas H Sarris; Nam H Dang; Michael Wang; Virginia Beasley; L Jeffrey Medeiros; Ruth L Katz; Harish Gagneja; Barry I Samuels; Terry L Smith; Fernando F Cabanillas Journal: J Clin Oncol Date: 2005-09-06 Impact factor: 44.544
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Hanneke C Kluin-Nelemans; Eva Hoster; Olivier Hermine; Jan Walewski; Christian H Geisler; Marek Trneny; Stephan Stilgenbauer; Florian Kaiser; Jeanette K Doorduijn; Gilles Salles; Michal Szymczyk; Hervé Tilly; Lothar Kanz; Christian Schmidt; Pierre Feugier; Catherine Thieblemont; Josée M Zijlstra; Vincent Ribrag; Wolfram Klapper; Christiane Pott; Michael Unterhalt; Martin H Dreyling Journal: J Clin Oncol Date: 2019-12-05 Impact factor: 44.544
Authors: James N Gerson; Elizabeth Handorf; Diego Villa; Alina S Gerrie; Parv Chapani; Shaoying Li; L Jeffrey Medeiros; Michael I Wang; Jonathon B Cohen; Oscar Calzada; Michael C Churnetski; Brian T Hill; Yazeed Sawalha; Francisco J Hernandez-Ilizaliturri; Shalin Kothari; Julie M Vose; Martin A Bast; Timothy S Fenske; Swapna Narayana Rao Gari; Kami J Maddocks; David Bond; Veronika Bachanova; Bhaskar Kolla; Julio Chavez; Bijal Shah; Frederick Lansigan; Timothy F Burns; Alexandra M Donovan; Nina Wagner-Johnston; Marcus Messmer; Amitkumar Mehta; Jennifer K Anderson; Nishitha Reddy; Alexandra E Kovach; Daniel J Landsburg; Martha Glenn; David J Inwards; Reem Karmali; Jason B Kaplan; Paolo F Caimi; Saurabh Rajguru; Andrew Evens; Andreas Klein; Elvira Umyarova; Bhargavi Pulluri; Jennifer E Amengual; Jennifer K Lue; Catherine Diefenbach; Richard I Fisher; Stefan K Barta Journal: J Clin Oncol Date: 2019-01-07 Impact factor: 44.544
Authors: Christian H Geisler; Arne Kolstad; Anna Laurell; Niels S Andersen; Lone B Pedersen; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Outi Kuittinen; Grete F Lauritzsen; Herman Nilsson-Ehle; Elisabeth Ralfkiaer; Måns Akerman; Mats Ehinger; Christer Sundström; Ruth Langholm; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen Journal: Blood Date: 2008-07-14 Impact factor: 22.113
Authors: Olivier Hermine; Eva Hoster; Jan Walewski; André Bosly; Stephan Stilgenbauer; Catherine Thieblemont; Michal Szymczyk; Reda Bouabdallah; Michael Kneba; Michael Hallek; Gilles Salles; Pierre Feugier; Vincent Ribrag; Josef Birkmann; Roswitha Forstpointner; Corinne Haioun; Mathias Hänel; René Olivier Casasnovas; Jürgen Finke; Norma Peter; Kamal Bouabdallah; Catherine Sebban; Thomas Fischer; Ulrich Dührsen; Bernd Metzner; Georg Maschmeyer; Lothar Kanz; Christian Schmidt; Richard Delarue; Nicole Brousse; Wolfram Klapper; Elizabeth Macintyre; Marie-Hélène Delfau-Larue; Christiane Pott; Wolfgang Hiddemann; Michael Unterhalt; Martin Dreyling Journal: Lancet Date: 2016-06-14 Impact factor: 79.321